YOLFTbeta
NFL Biosciences SAS

NFL Biosciences SAS

ALNFL · PA · Healthcare / Biotechnology

0.353EUR-0.02 (-5.87%)

Price History

Full chart

Market Stats

Previous Close0.375
Open0.388
Day Range0.342 – 0.42
52-Week Range0.64 – 1.85
Volume320.47K
Market Cap8.48M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.26
Dividend Yield0.00%
Beta1.15
50-Day Avg0.8367
200-Day Avg1.01

About

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Bruno Lafont M.B.A., M.Sc.
  • Employees4
  • Headquarters199 Rue HElEne Boucher, Castelnau-le-Lez, France, 34170, France
  • Websitehttps://www.nflbiosciences.com

Leadership

  • Mr. Bruno Lafont M.B.A., M.Sc.Founder, CEO, MD & Chairman
  • Mr. Guillaume AudemaChief Financial Officer
  • Dr. Ignacio Faus M.B.A., Ph.D.MD & Director
  • Dr. Yannick Pletan M.D., M.Sc.Chief Medical Officer & Director · b. 1953
  • Ms. Lara Babich Ph.D.Head of Development & Manufacturing

Financials

Income Statement

Currency: EUR2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue03390200.01K460
Growth (%)--+1200.00%-100.00%--99.98%-100.00%
Cost of Revenue253.87K169.36K530.73K2.24M56.06K1.55M2.52M
Gross Profit-253.87K-169.36K-530.73K-2.24M-56.06K-67.14K-2.52M
Gross Margin--5645300.00%-1360853.85%--28.03%-145963.04%-
Operating Expense93.42K148.67K371.13K777.81K4.37M2.72M1.35M
Operating Income-347.30K-318.03K-901.87K-3.01M-4.43M-2.79M-3.87M
Operating Margin--10600933.33%-2312479.49%--2215.09%-6065415.22%-
EBITDA-303.61K-271.09K-1.08M-2.81M-4.05M-2.65M-3.79M
EBITDA Margin--9036366.67%-2757612.82%--2024.54%-5758256.52%-
Net Income-267.96K-266.49K-978.24K-2.44M-3.75M-2.08M-3.32M
Net Income Margin--8882866.67%-2508317.95%--1872.64%-4523563.04%-
Interest Expense3764.99K5384936.51K30414.19K
Interest Expense % of Total Revenue-166200.00%1379.49%-3.25%660.87%-

Balance Sheet

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets265.88K466.99K576.64K3.69M2.40M3.97M3.61M3.66M
Total Liabilities188.79K55.47K426.61K397.73K1.55M3.62M2.63M3.36M
Total Equity77.09K411.52K150.03K3.29M844.00K349.94K976.43K306.14K
Cash69.95K224.93K310.20K3.04M1.05M2.34M1.91M2.00M
Total Debt50.00K-85.00K170.01K83.26K62.17K40.98K582.59K
Net Debt-19.95K-224.93K-225.20K-2.95M-970.33K-2.28M-1.87M-1.42M

Cash Flow

Currency: EUR2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-83.91K87.00K104.89K---
Capital Expenditure0000000
Free Cash Flow-83.91K87.00K104.89K---
FCF to OCF-100.00%100.00%100.00%---

Earnings

Report DateOct 4, 2021Apr 29, 2022Oct 26, 2022Jun 20, 2023Oct 16, 2025
EPS Estimate0.000.000.000.000.00
EPS Actual-0.04-0.16-0.20-0.260.00
Surprise-----
TimingPre-market--Pre-market-

Key Statistics & Ratios

Market Cap8.48M
Enterprise Value7.75M
Trailing P/E0.00
Forward P/E0.00
Price / Sales45094.31
Price / Book30.59
EPS-0.26
Book Value0.024
Revenue (TTM)188
Gross Profit (TTM)-2.52M
EBITDA-3.79M
Profit Margin0.00%
Operating Margin-5838226.60%
Return on Equity-517.39%
Return on Assets-66.56%
Shares Outstanding12.67M
Shares Float8.10M
Beta1.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%